<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04185272</url>
  </required_header>
  <id_info>
    <org_study_id>IMMUNOCOL-IPC 2019-018</org_study_id>
    <nct_id>NCT04185272</nct_id>
  </id_info>
  <brief_title>Butyrophilins Role in Colon Cancer</brief_title>
  <official_title>Role of Butyrophilins in Colon Cancers Aggressiveness Evaluation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut Paoli-Calmettes</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institut Paoli-Calmettes</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      quantification of BTNL molecules in colon cancer in order to determinate if their could be
      used as a prognostic marquer
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">February 2020</start_date>
  <completion_date type="Anticipated">February 2028</completion_date>
  <primary_completion_date type="Anticipated">February 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>colon cancer patients and metastatic colon cancer patients will be included in this study. We expect that BTNL molecules expression is different depending of the aggressiveness of the illness</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>evaluation of BTNL3, BTNL8 and BTNL9 expression by transcriptomics and immunohistochemistry</measure>
    <time_frame>8 years</time_frame>
    <description>healthy and cancerous colon ad metastasis (if applicable) will be analysed by</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Colonic Cancer</condition>
  <arm_group>
    <arm_group_label>non-metastatic colon cancer</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>metastatic colon cancer</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>analysis of BTN and BTNL status</intervention_name>
    <description>analysis of BTN and BTNL expression in colon cancer and hepatic metastasis</description>
    <arm_group_label>metastatic colon cancer</arm_group_label>
    <arm_group_label>non-metastatic colon cancer</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient is older than 18 years old,

          -  Signed participation consent,

          -  Non-metastatic colon cancer immediately resectable or metastatic and liver synchronous
             for which it was decided a combined colic and liver surgery (metastatic patient at the
             outset) in multidisciplinary consultation meeting.

          -  Performance Status (PS) 0 or 1

          -  affiliated to the social security or beneficiary

        Exclusion Criteria:

          -  Rectal cancer, colon cancer recurrence

          -  Emergency of colon cancer Surgery

          -  History of inflammatory disease of the digestive tract (Crohn's disease or ulcerative
             colitis)

          -  Patient who received neoadjuvant therapy other than chemotherapy

          -  Patient treated with immune-suppressors or long-course corticosteroids &lt;12 months

          -  Pregnant women or likely to be pregnant (without effective contraception) or
             breastfeeding,

          -  Person in urgent situation, person under legal protection measure, or unable to
             express his / her consent,

          -  Impossibility of submitting to the medical examination of the test for geographical,
             social or psychological reasons
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Dominique Genre, Dr</last_name>
    <phone>04 91 22 37 78</phone>
    <email>drci.up@ipc.unicancer.fr</email>
  </overall_contact>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>December 2, 2019</study_first_submitted>
  <study_first_submitted_qc>December 2, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 4, 2019</study_first_posted>
  <last_update_submitted>December 6, 2019</last_update_submitted>
  <last_update_submitted_qc>December 6, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 10, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colonic Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

